U.S. markets close in 6 hours
  • S&P 500

    3,627.26
    -11.09 (-0.30%)
     
  • Dow 30

    29,677.93
    -232.44 (-0.78%)
     
  • Nasdaq

    12,197.64
    -8.21 (-0.07%)
     
  • Russell 2000

    1,846.60
    -8.67 (-0.47%)
     
  • Crude Oil

    45.34
    -0.19 (-0.42%)
     
  • Gold

    1,774.80
    -13.30 (-0.74%)
     
  • Silver

    22.26
    -0.38 (-1.67%)
     
  • EUR/USD

    1.1999
    +0.0029 (+0.24%)
     
  • 10-Yr Bond

    0.8490
    +0.0070 (+0.83%)
     
  • GBP/USD

    1.3372
    +0.0058 (+0.44%)
     
  • USD/JPY

    104.2370
    +0.1520 (+0.15%)
     
  • BTC-USD

    19,576.35
    +242.52 (+1.25%)
     
  • CMC Crypto 200

    385.00
    +20.40 (+5.60%)
     
  • FTSE 100

    6,348.21
    -19.37 (-0.30%)
     
  • Nikkei 225

    26,433.62
    -211.09 (-0.79%)
     

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Strongbridge Biopharma plc (SBBP) Investigation

·2 min read

NEW YORK, NY / ACCESSWIRE / September 14, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Strongbridge Biopharma plc ("Strongbridge" or the "Company") (NASDAQ:SBBP). Investors who purchased Strongbridge securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/sbbp.

The investigation concerns whether Strongbridge and certain of its officers and/or directors have violated federal securities laws.

On September 8, 2020, Strongbridge issued a press release entitled "Strongbridge Biopharma's Recorlev successful in Cushing's syndrome study." While the press release touted "positive results from [Strongbridge's] 44-subject Phase 3 clinical trial, LOGIC, evaluating Recorlev (levoketoconazole) in patients with endogenous Cushing's syndrome," the press release also disclosed treatment-emergent adverse events" that included "nausea (29%), hypokalemia (28%), headache (21%), hypertension (19%) and diarrhea (15%)." On this news, Strongbridge's stock price fell $0.71 per share, or 20.11%, to close at $2.82 per share on September 8, 2020.

If you are aware of any facts relating to this investigation, or purchased Strongbridge shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/sbbp. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/605895/Bronstein-Gewirtz-Grossman-LLC-Notifies-Shareholders-of-Strongbridge-Biopharma-plc-SBBP-Investigation